Stock

AbbVie

ABBV

Drug Manufacturers - General · Healthcare

Also trades as: 0QCV.L GBP 2.84 (+1.44%)

Price

$284.70

-0.49 (-0.17%)

Market Cap

$503.10B

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Data as of Oct 23, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality

Strong

23/30

Growth

Good

10/20

Cash Flow

Exceptional

10/10

Stability

Mixed

3/10

Valuation

Good

5/10

Ownership

Weak

1/15

Dividends

Good

3/5

55 of 100 counted points = Winston Score 55.

Track this stock — start free trial

§Winston Score History

The full picture

AbbVie is a large pharmaceutical company that discovers, makes, and sells prescription medicines. Its biggest product is Humira, a drug used to treat conditions like rheumatoid arthritis and Crohn's disease, which was once the best-selling drug in the world. AbbVie also sells cancer treatments, eye care drugs, and medicines for mental health conditions, selling mostly to hospitals, pharmacies, and insurance-covered patients.

AbbVie makes money by selling branded prescription drugs, which carry high prices and strong profit margins, reflected in its 70% gross margin. The company operates globally, with the United States generating the majority of its revenue, and it ranks among the largest drug makers in the world by market value. The key challenge AbbVie faces is replacing lost Humira revenue, since cheaper copycat versions of that drug have entered the market — the company is betting on newer drugs like Skyrizi and Rinvoq to fill that gap.

Politician Trades

39 trades / 12mo

21 Congressional buys and 18 sells on ABBV in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+10.2% YoY

YoY Growth Rate

Steady revenue growth

Reported EPS Growth

+284.9% YoY

Quarterly reporting periods ended:

30 Jun 2025: $0.53

30 Jun 2026: $2.04

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS increased year over year

R&D Spend

$9.1B/ year

↓ Declining (-29% vs prior year)

14.9% of revenue

In line with sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$6.8B cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth + cash flow

AbbVie is a rare growth stock that's already generating positive cash flow while growing at 10%. The Winston Score doesn't fully credit this transition from "burner" to "earner."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

−0.2% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 1.78B (2021) → 1.77B (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

74.7%

Premium pricing power — 74.7% gross margin

Profit after running costs

Operating Margin

37.9%

Excellent — 37.9% operating margin

Return on the money invested

ROCE

9.9%

Below par — 9.9% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+10.4%

Steady sales growth (+10.4% YoY)

Profit growth

EPS YoY

+68.1%

Earnings growing fast (+68.1% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

309%

Turns 309% of profit into real cash

Spare cash per sale

FCF Margin

28.3%

Converts sales into free cash efficiently (28.3%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

49.22

Heavy debt load (49.22)

Covers its interest

Interest Cover

6.47x

Adequate interest coverage (6.5x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

80.2x

Expensive — P/E 80.2

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year

P/E vs Forward

+65.4

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (80.2 → 14.8)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

2.62%

Moderate income — 2.62% yield

Standard yield zone for stable dividend payers. A meaningful piece of total return.

Dividend record

Dividend Growth

+5.5%

Dividend growing modestly (5.5% YoY)

Payout Ratio

190%

no trend

Paying out more than the last 12 months of profit. The dividend is being funded from cash or borrowing, not this year’s earnings.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial